目的:这项研究的目的是确定非小细胞肺癌肺下切除术前100名最常用的参考研究。
方法:我们通过搜索WebofScience数据库,确定了前100名最常用的非小细胞肺癌肺叶下切除术研究。我们从选定的研究中提取关键信息,包括作者,journal,影响因子,文章类型,出版年份,国家,组织,和关键字。
结果:据我们了解,这是对非小细胞肺癌肺叶下切除术的首次文献计量学研究。最常引用的前100项研究的出版年份从1994年到2022年,引文计数从51到795不等。大多数纳入的研究是原始研究(93/100),主要是回顾性研究(82/93)。美国在发表的文章和引用方面领先,胸外科年鉴是最常见的来源期刊(n=27)。高密度关键词主要来源于有限切除,肺叶切除术,生存,癌,复发,随机试验,放射治疗,肺癌,结果,2厘米,正如CiteSpace分析所揭示的那样。
结论:我们的研究汇总并分析了非小细胞肺癌肺下切除术领域最常用的100项研究。美国在这一主题上发表和引用最多的作品。目前,肺下切除术研究的热门关键词正逐渐向预后转移,并获得更好的循证医学证据,以证明其在非小细胞肺癌治疗中的价值。
OBJECTIVE: The goal of this research is to pinpoint the top 100 most frequently referenced studies on sublobectomy for non-small cell lung cancer.
METHODS: We identified the top 100 most frequently referenced studies on sublobectomy for non-small cell lung cancer by searching the Web of Science database. We extracted key information from the selected studies, including the author, journal, impact factor, type of article, year of publication, country, organization, and keyword.
RESULTS: To the best of our understanding, this is the inaugural bibliometric study on sublobectomy for non-small cell lung cancer. The publication years of the top 100 most frequently referenced studies span from 1994 to 2022, with citation counts ranging from 51 to 795. The majority of the included studies are original (93/100) and primarily retrospective studies (82/93). The United States leads in terms of published articles and citations, with the Annals of Thoracic Surgery being the most frequently sourced journal (n = 27). High-density keywords primarily originate from limited resection, lobectomy, survival, carcinoma, recurrence, randomized trial, radiotherapy, lung cancer, outcome, 2 cm, as revealed by CiteSpace analysis.
CONCLUSIONS: Our research compiles and analyzes the top 100 most frequently referenced studies in the field of sublobectomy for non-small cell lung cancer. The United States has the most published and cited works on this topic. Currently, the hot keywords for sublobectomy research are gradually shifting towards prognosis and obtaining better evidence-based medical evidence to demonstrate its value in the treatment of non-small cell lung cancer.